{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T15:48:58Z","timestamp":1716133738384},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,5,27]],"date-time":"2009-05-27T00:00:00Z","timestamp":1243382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1007\/s00403-009-0961-7","type":"journal-article","created":{"date-parts":[[2009,5,26]],"date-time":"2009-05-26T03:00:43Z","timestamp":1243306843000},"page":"429-442","source":"Crossref","is-referenced-by-count":11,"title":["Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab"],"prefix":"10.1007","volume":"301","author":[{"given":"Robert","family":"Bissonnette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard G.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Papp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Matheson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darryl","family":"Toth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micki","family":"Hultquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory P.","family":"Geba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,27]]},"reference":[{"key":"961_CR1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1006\/smim.1993.1029","volume":"5","author":"BE Bierer","year":"1993","unstructured":"Bierer BE, Hahn WC (1993) T cell adhesion, avidity regulation and signaling: a molecular analysis of CD2. Semin Immunol 5:249\u2013261. doi: 10.1006\/smim.1993.1029","journal-title":"Semin Immunol"},{"key":"961_CR2","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1097\/00007890-199911270-00026","volume":"68","author":"L Branco","year":"1999","unstructured":"Branco L, Barren P, Mao SY, Pfarr D, Kaplan R, Postema C, Langermann S, Koenig S, Johnson S (1999) Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells. Transplantation 68:1588\u20131596. doi: 10.1097\/00007890-199911270-00026","journal-title":"Transplantation"},{"key":"961_CR3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJM200107263450403","volume":"345","author":"CN Ellis","year":"2001","unstructured":"Ellis CN, Krueger GG, Alefacept Clinical Study Group (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345:248\u2013255. doi: 10.1056\/NEJM200107263450403","journal-title":"N Engl J Med"},{"key":"961_CR4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00128071-200708020-00005","volume":"8","author":"CN Ellis","year":"2007","unstructured":"Ellis CN, Barker JN, Haig AE, Parker CA, Daly S, Jayawardene DA, Avandia Psoriasis Study Group (2007) Placebo response in two long-term randomized psoriasis studies that were negative for rosiglitazone. Am J Clin Dermatol 8:93\u2013102. doi: 10.2165\/00128071-200708020-00005","journal-title":"Am J Clin Dermatol"},{"key":"961_CR5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1517\/14728214.7.1.69","volume":"7","author":"R Gniadecki","year":"2002","unstructured":"Gniadecki R, Calverley MJ (2002) Emerging drugs in psoriasis. Expert Opin Emerg Drugs 7:69\u201390. doi: 10.1517\/14728214.7.1.69","journal-title":"Expert Opin Emerg Drugs"},{"key":"961_CR6","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","volume":"55","author":"KB Gordon","year":"2006","unstructured":"Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM (2006) Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55:598\u2013606. doi: 10.1016\/j.jaad.2006.05.027","journal-title":"J Am Acad Dermatol"},{"key":"961_CR7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0733-8635(05)70376-4","volume":"14","author":"J Koo","year":"1996","unstructured":"Koo J (1996) Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 14:485\u2013496. doi: 10.1016\/S0733-8635(05)70376-4","journal-title":"Dermatol Clin"},{"key":"961_CR8","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1067\/mjd.2002.127247","volume":"47","author":"GG Krueger","year":"2002","unstructured":"Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN, Alefacept Clinical Study Group (2002) A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47:821\u2013833. doi: 10.1067\/mjd.2002.127247","journal-title":"J Am Acad Dermatol"},{"key":"961_CR9","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa062382","volume":"356","author":"GG Krueger","year":"2007","unstructured":"Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M, CNTO 1275 Psoriasis Study Group (2007) A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356:580\u2013592. doi: 10.1056\/NEJMoa062382","journal-title":"N Engl J Med"},{"key":"961_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mjd.2002.120568","volume":"46","author":"JG Krueger","year":"2002","unstructured":"Krueger JG (2002) The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46:1\u201323. doi: 10.1067\/mjd.2002.120568","journal-title":"J Am Acad Dermatol"},{"key":"961_CR11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.139.6.719","volume":"139","author":"M Lebwohl","year":"2003","unstructured":"Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE, Alefacept Clinical Study Group (2003) An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139:719\u2013727. doi: 10.1001\/archderm.139.6.719","journal-title":"Arch Dermatol"},{"key":"961_CR12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Sect. 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58:826\u2013850. doi: 10.1016\/j.jaad.2008.02.039","journal-title":"J Am Acad Dermatol"},{"key":"961_CR13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00403-007-0744-y","volume":"299","author":"A Nast","year":"2007","unstructured":"Nast A et al (2007) German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 299:111\u2013138. doi: 10.1007\/s00403-007-0744-y","journal-title":"Arch Dermatol Res"},{"key":"961_CR14","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1067\/mjd.2001.117850","volume":"45","author":"K Papp","year":"2001","unstructured":"Papp K et al (2001) The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 45:665\u2013674. doi: 10.1067\/mjd.2001.117850","journal-title":"J Am Acad Dermatol"},{"key":"961_CR15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00403-006-0660-6","volume":"298","author":"KA Papp","year":"2006","unstructured":"Papp KA (2006) The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 298:7\u201315. doi: 10.1007\/s00403-006-0660-6","journal-title":"Arch Dermatol Res"},{"key":"961_CR16","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","volume":"366","author":"K Reich","year":"2005","unstructured":"Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE, EXPRESS study investigators (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366:1367\u20131374. doi: 10.1016\/S0140-6736(05)67566-6","journal-title":"Lancet"},{"key":"961_CR17","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMra041320","volume":"352","author":"MP Schon","year":"2005","unstructured":"Schon MP, Boehncke WH (2005) Psoriasis. N Engl J Med 352:1899\u20131912. doi: 10.1056\/NEJMra041320","journal-title":"N Engl J Med"},{"key":"961_CR18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2005.06893.x","volume":"153","author":"CH Smith","year":"2005","unstructured":"Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, Finlay AY, Griffiths CE, Jackson K, McHugh NJ, McKenna KE, Reynolds NJ, Ormerod AD, British Association of Dermatologists (2005) British association of dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 153:486\u2013497. doi: 10.1111\/j.1365-2133.2005.06893.x","journal-title":"Br J Dermatol"},{"key":"961_CR19","doi-asserted-by":"crossref","unstructured":"Spuls PI, Witkamp L, Bossuyt PM, Bos JD (2004) The course of chronic plaque-type psoriasis in placebo groups of randomized controlled studies. Arch Dermatol 140:338\u2013344 (discussion 344). doi: 10.1001\/archderm.140.3.338","DOI":"10.1001\/archderm.140.3.338"},{"key":"961_CR20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2133.2004.06070.x","volume":"151","author":"W Sterry","year":"2004","unstructured":"Sterry W et al (2004) Biological therapies in the systemic management of psoriasis: International consensus conference. Br J Dermatol 151:3\u201317. doi: 10.1111\/j.1365-2133.2004.06070.x","journal-title":"Br J Dermatol"},{"key":"961_CR21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jaad.2005.04.011","volume":"53","author":"VD Thomas","year":"2005","unstructured":"Thomas VD, Yang FC, Kvedar JC (2005) Biologics in psoriasis: a quick reference guide. J Am Acad Dermatol 53:346\u2013351. doi: 10.1016\/j.jaad.2005.04.011","journal-title":"J Am Acad Dermatol"},{"key":"961_CR22","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2007.07.016","volume":"57","author":"DC Torti","year":"2007","unstructured":"Torti DC, Feldman SR (2007) Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 57:1059\u20131068. doi: 10.1016\/j.jaad.2007.07.016","journal-title":"J Am Acad Dermatol"},{"key":"961_CR23","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1517\/14728214.11.4.567","volume":"11","author":"GA Vena","year":"2006","unstructured":"Vena GA, Cassano N (2006) Emerging drugs for psoriasis. Expert Opin Emerg Drugs 11:567\u2013596. doi: 10.1517\/14728214.11.4.567","journal-title":"Expert Opin Emerg Drugs"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-009-0961-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00403-009-0961-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-009-0961-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T13:37:41Z","timestamp":1559050661000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00403-009-0961-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,27]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["961"],"URL":"https:\/\/doi.org\/10.1007\/s00403-009-0961-7","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,27]]}}}